NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces CE Mark for NGS-Based MammaPrint BluePrint Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe
IRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Read More
Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint BluePrint Breast Cancer Kit to Market
IRVINE, CA, AMSTERDAM, and RIJSWIJK, NETHERLANDS – 19 December 2017 – Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, and Bluebee, a company driving global genomic data-driven medicine, have partnered to Read More
Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients
Data from the I-SPY 2 trial showed the first long-term survival results for patients pre-selected as MammaPrint high-risk, with 94% of the patients who achieved pathological complete response event-free at three years MammaPrint assessment Read More
Agendia and UZ Leuven Partner to Co-Validate MammaPrint BluePrint Breast Cancer Risk of Recurrence and Molecular Subtyping Kit Ahead of European Launch
IRVINE, CA, AMSTERDAM, NETHERLANDS – 7 December 2017 – Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and University Hospitals Leuven (UZ Leuven) in Belgium have partnered to co-validate Agendia’s new in Read More
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint BluePrint Breast Cancer Kit Co-Validation Study
Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit IRVINE, CA, AMSTERDAM, and PARIS – 5 December 2017 – Read More
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint and BluePrint Across Breast Cancer Patient Populations
IRVINE, CA, AMSTERDAM, NETHERLANDS – 30 November 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Read More
Agendia’s MammaPrint Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code
CMS established the 2018 payment rate for MammaPrint’s new CPT code 81521 thus securing continued access to MammaPrint for Medicare/Medicaid beneficiaries The new determination and increased allowance follows an impressive Q3 which saw MammaPrint’s U.S. Read More
